Shots:

• The approval is based on the data from PK bridging studies and P-III EVOLVE-MS-2 study to evaluate the GI tolerability of Vumerity vs Tecfidera in patients with relapsing-remitting MS
• In the EVOLVE-MS-2 study, the therapy demonstrated a low rate of overall treatment discontinuation due to GI tolerability (1.6% vs 6%). Additionally, flushing was reported in patients treated with Vumerity & Tecfidera (32.8% & 40.6%), no serious events of flushing or discontinuations were observed
• Vumerity is oral fumarate & has received the US FDA approval in Oct 2019. The therapy is also approved in Great Britain and Switzerland

/ article Ref: Globe Newswire | Image: Biogen